Publications by authors named "E V Harrold"

Harrold et al. evaluate the fertility impact of checkpoint inhibitor blockade (ICB), demonstrating that unlike in utero exposure, post-exposure conception appears to result in uncomplicated pregnancies and healthy progeny. They demonstrate contemporaneous monitoring of temporal female hormonal fluctuations before, on, and post ICB exposure and prior to successful embryo implantation.

View Article and Find Full Text PDF
Article Synopsis
  • Adjuvant mFOLFIRINOX (mFFX) is a standard treatment for patients with resected pancreatic ductal adenocarcinoma (PDAC), but there is limited information on its effectiveness outside of clinical trials.
  • A study of 147 patients showed a median recurrence-free survival (RFS) of 26 months, with some patients over 70 years experiencing a median overall survival (OS) of 51 months.
  • Starting mFFX treatment within 8 weeks of surgery was linked to better survival outcomes, while certain genetic factors like KRAS mutations suggested poorer RFS and OS.
View Article and Find Full Text PDF

Background: Neonatal resuscitation airway training can be difficult as there is no feedback on the face mask technique. "JUNO" is a training respiratory function monitor that provides feedback on mask leak, ventilatory rate, and tidal volume.

Objective: To evaluate whether the use of the JUNO improves face mask ventilation techniques in manikin models.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the role of microsatellite instability (MSI-H) in pancreatic cancer (PC) associated with Lynch syndrome (LS), focusing on both germline and somatic variants that affect mismatch repair genes.
  • It involves a retrospective analysis of 55 PC patients at Memorial Sloan Kettering Cancer Center, revealing that a significant portion of those with LS and somatic MMR variants exhibit MSI-H status, which could impact treatment responses to immune therapy.
  • Results showed that 59% of LS cohort patients had MSI-H, whereas 43% in the somatic MMR cohort had the same status, suggesting distinct genetic characteristics and age differences at diagnosis between the two groups.
View Article and Find Full Text PDF

Locally advanced gastrointestinal (GI) malignancies have conventionally been treated in a multimodal fashion that combines (neo)adjuvant chemotherapy with or without radiation and definitive surgical resection. Clinical data have demonstrated the reduced responsiveness of GI malignancies with microsatellite instability (MSI) to both adjuvant and neoadjuvant systemic chemotherapy when compared with microsatellite stable (MSS) disease. The elevated tumor mutational burden associated with MSI tumors of all types sensitizes these tumors to the effects of immune checkpoint blockade in the metastatic setting, which led to tumor-agnostic approval of immune checkpoint inhibitors in this context.

View Article and Find Full Text PDF